TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02749162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: After the block regression, at the first analgetic request the patients received the analgesia protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: After the block regression, at the first analgetic request the patients received the analgesia protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: After the block regression, at the first analgetic request the patients received the analgesia protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: After the block regression, at the first analgetic request the patients received the analgesia protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: After the block regression, at the first analgetic request the patients received the analgesia protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: After the block regression, at the first analgetic request the patients received the analgesia protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
Study: NCT02781987

Intervention type: OTHER
Intervention: chronic pancreatitis
Description: patients with chronic pancreatitis
Study: NCT02085265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
Study: NCT02768402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caisson TMVR System
Description: Transcatheter mitral valve replacement is a percutaneous procedure used to treat mitral valve regurgitation with a prosthetic valve implantation.
Study: NCT04849117

Intervention type: PROCEDURE
Intervention: Ultrasound guided Bilateral Transversus Thoracis Muscle Plane block
Description: In the TTMP block group, an ultrasounded guided TTMP block was performed by an anesthesiologist, in ICU, before tracheal tube removal. Between the 4th et 5th rib, on each side, 40 ml of Ropivacaine 2 mg/ml, in association with Clonidine, was injected single-shot in the tranversus thoracis muscle plane. The targets of local anesthetic were the anterior branches of intercostal nerves from T2 to T6. Dexamethasone 8 mg was injected intravenously.
Study: NCT01707628

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccination with influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccination with influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccination with influenza vaccine
Study: NCT02406456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Study: NCT01659840

Intervention type: RADIATION
Group type: OTHER
Intervention: Red laser
Description: On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.

Intervention type: RADIATION
Group type: OTHER
Intervention: Infrared laser
Description: On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
Study: NCT05510414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological intervention based on psychological capital
Description: Psychological capital would be modified via various training programs in order to manage burnout among nurses. When the four core psychological resources are combined, they may form a higher-order construct that predicts attitudes and performance more strongly than any of the four components by themselves .
Study: NCT04240223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilacidin
Description: Brilacidin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilacidin
Description: Brilacidin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilacidin
Description: Brilacidin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4Mq 99mTc-DTPA
Description: 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4Mq 99mTc-DTPA
Description: 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4Mq 99mTc-DTPA
Description: 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: 4Mq 99mTc-DTPA
Description: 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: 4Mq 99mTc-DTPA
Description: 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: 4Mq 99mTc-DTPA
Description: 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
Study: NCT02356757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Behavioral Intervention
Description: The PBI is based on self-regulation theory, the Transtheoretical Model and Prospect Theory, and will be delivered using Motivational Interviewing principles and the teach-back method. Participants will receive monthly calls targeting foot self-care, foot self-monitoring, diet, medication and physical activity for 6 months. Call/mailing frequency during the next 6 months will depend on adherence level to foot self-care and self-monitoring at 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Current Best Practice
Description: CBP will include monthly calls from a counselor focusing on preventing conditions like colorectal cancer, flu, insomnia, vision problems, memory loss and oral disease for the first 6 months. Frequency of calls and mailings from counselors during the next 6 months will be determined by level of adherence to preventive strategies during the first 6 months.
Study: NCT05423457

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vegan diet
Description: The participants were advised to eat foods in their original type.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: The participants were advised to eat foods in their original type.
Study: NCT01265394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] Flutemetamol
Description: Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
Study: NCT02258217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
Study: NCT01853787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate
Description: Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
Study: NCT03132506

Intervention type: OTHER
Intervention: patient-reported-outcomes
Description: Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes

Intervention type: OTHER
Intervention: patient-reported-outcomes
Description: Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
Study: NCT01853787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
Study: NCT04250116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC monotherapy
Description: Patients enrolled in the NOAC monotherapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (15 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antithrombotic therapy with NOAC and clopidogrel
Description: Patients enrolled in the dual antithrombotic therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 15 mg once daily and clopidogrel 75 mg daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
Study: NCT04350463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: CC-90011
Study: NCT01853787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
Study: NCT01517633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BirthSign
Description: When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.
Study: NCT02607501

Intervention type: DEVICE
Group type: OTHER
Intervention: Implant eCLIPs
Description: Implant eCLIPs at target bifurcation aneurysm
Study: NCT03301987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: 30 minutes per day of therapeutic exercise
Study: NCT01351454

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT HEALTHY
Description: ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nondirective Therapy (NDT)
Description: In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
Study: NCT00627562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System
Description: Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
Study: NCT00669188

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Information absent
Description: Information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: Information
Study: NCT00225186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visanne (SH T00660AA , BAY86-5258)
Description: Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
Study: NCT03624491

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal pressure measurement guided ventilation
Description: Use of esophageal pressure measurements to guide mechanical ventilation
Study: NCT01885832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose tissue stromal vascular fraction
Study: NCT02028507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study: NCT04350463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: CC-90011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: CC-90011
Study: NCT04917354

Intervention type: DEVICE
Intervention: Superb-Microvascular imaging
Description: Device: Superb-Microvascular imaging Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
Study: NCT04167189

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine gel
Description: Septodont 5% oral lidocaine gel (NDC 0362-0221-10), 75 mg
Study: NCT03887182

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: Additional sequence (DTI) and functional MRI (fMRI) during the MRI which is done as part of the usual care

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: functional MRI
Description: Additional sequence (DTI) and functional MRI (fMRI) during the MRI which is done as part of the usual care

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: Additional sequence (DTI) and functional MRI (fMRI) during the MRI which is done as part of the usual care

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Automated Cortical Brainstem Auditory Evoked Potential
Description: Automated Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Automated Cortical Brainstem Auditory Evoked Potential
Description: Automated Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Automated Cortical Brainstem Auditory Evoked Potential
Description: Automated Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: whole exome sequencing
Description: A study of all the DNA-encoding exons of the child/parent from a sample taken as part of the usual care

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cortical Brainstem Auditory Evoked Potential
Description: Standard Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary consultation
Description: multidisciplinary consultation is composed of:~* an ENT consultation and audiometry~* a speech therapy assessment~* a psychometric evaluation
Study: NCT02378948

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid oral feeding
Description: Liquid oral feeding (water, soup, porridge, nutritional supplements etc.)
Study: NCT02091414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (MMF)
Description: 1.0 g PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A (CsA)
Description: Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: As per the practice of each participating center
Study: NCT04350463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study: NCT04472598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Navitoclax
Description: Tablet; Oral
Study: NCT03825081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine, pilocarpine
Description: 1 drop of pilocarpine (0.5%)~1 drop of brimonidine (0.2%)
Study: NCT03850834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammoxetine Hydrochloride Enteric-coated Tablets
Description: There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo enteric-coated tablets
Description: There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
Study: NCT03168451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Text Messages
Description: Members of the intervention group receive culturally tailored messages on the following schedule: 4 messages per day for 1 week prior to target quit date, 4 messages per day for 4 weeks following target quit date, 3 messages per week for 20 weeks following weeks.
Study: NCT03821766

Intervention type: DEVICE
Intervention: Ballistocardiography and seismocardiography
Description: SCG and BCG signals will be recorded by the mean of an unobtrusive and friendly device consisting of two houses, the first one placed on the sternum and the second one place on the lumbar region near the subject's center of mass. The signal will be transferred to a tablet by Bluetooth and tracings will be analysed automatically with Matlab. The SCG+BCG signals are synchronized to the intracardiac pressure tracings in order to allow a comparative interpretation between the two tracings.
Study: NCT02040753

Intervention type: BEHAVIORAL
Intervention: Intensive Lifestyle Intervention
Description: Intensive Lifestyle intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction. Education within Nutrition, exercise and healthy living in general.
Study: NCT02332941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.
Study: NCT00156026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: loop electrosurgical excision procedure (LEEP)
Description: 1. loop electrosurgical excision procedure
Study: NCT03628378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verasense
Description: Ligamentous balancing device
Study: NCT03867175

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Patients undergo 3-10 treatments of stereotactic body radiation therapy (SBRT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients undergo 3-10 treatments of SBRT. Patients also receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
Study: NCT04135703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Prevention Services + Housing
Description: opioid and related prevention services in addition to 6 months of rental assistance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Prevention Services Only
Description: opioid and related prevention services for 6 months